NEW YORK–(BUSINESS WIRE<\/a>)–Establishment Labs<\/a> Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women\u2019s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has surpassed more than five million Motiva devices in market.<\/p>\n \nThis milestone underscores the company\u2019s long\u2011standing commitment to science\u2011based innovation and reflects sustained global adoption of Motiva\u2019s portfolio of breast aesthetics and reconstruction solutions across more than 100 countries worldwide.<\/p>\n \n\u201cSurpassing five million Motiva devices is another milestone for our company, and a clear reflection that our investment in bringing better technology and procedures to market is rewarded by strong consumer adoption,\u201d said Peter Caldini, Chief Executive Officer of Establishment Labs. \u201cJust three years ago, we announced that we had exceeded three million devices, and we continue to gain market share while expanding the category. Our over 25% revenue growth in 2025 has continued into 2026, driven by the successful entry of Motiva in the United States and the global momentum of our minimally invasive platform.\u201d<\/p>\n \n\u201cEstablishment Labs has changed what is possible for our patients,\u201d said Mark Epstein, MD, F.A.C.S., a board-certified plastic surgeon in Hauppauge, New York. \u201cBy rethinking device design through the lens of science, safety, and the real needs of women, they have provided more than 2.5 million women worldwide with advanced options that are clinically shown to be best in class. I am delivering better patient outcomes and my practice has more than doubled. In the first quarter of 2026, I had 56 patients choose the Preserv\u00e9 minimally invasive procedure, and in the last six months I have completed 90 cases. I already have 50 Preserv\u00e9 cases scheduled for Q2. Preserv\u00e9 is priced 30% higher than my standard Motiva Breast Augmentation, because patients are willing to spend more for a procedure and technology that avoids general anesthesia, preserves native breast tissue and their chest muscles, and supports faster recovery.\u201d<\/p>\n About Establishment Labs<\/span><\/b><\/p>\n \nEstablishment Labs Holdings Inc. is a global medical device company dedicated to improving women\u2019s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 100 countries. With five million Motiva\u00ae devices delivered to plastic and reconstructive surgeons since 2010, the company\u2019s products have created a new standard for safety and patient satisfaction. The company\u2019s minimally invasive platform consists of Mia Femtech\u00ae, a unique minimally invasive experience for breast harmonization, and Preserv\u00e9\u2122, a breast tissue preserving and minimally invasive technology for primary breast augmentation and primary mastopexy augmentation. GEM\u00ae is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora\u00ae tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor\u2122 is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company\u2019s first biosensor Zen\u00ba\u2122, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at www.establishmentlabs.com<\/a>.<\/p>\n Forward-Looking Statements<\/span><\/b><\/p>\n \nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d). You can find many (but not all) of these statements by looking for words such as \u201capproximates,\u201d \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cintends to,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cmay\u201d or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company\u2019s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and\/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the company’s annual report on Form 10-K filed on February 27, 2026, which risks and uncertainties may be updated in the future in other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260407447600\/en\/<\/a><\/span><\/p>\n \nInvestor\/Media Contact: KEYWORDS:<\/b> New York United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Oncology Health Medical Devices Consumer Women Surgery Health Technology<\/p>\n<\/p>\n
\n
Malavika William
\n
Mwilliam@establishmentlabs.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260407447600\/en\/2766953\/3\/getsitelogo.jpg\")
<\/td>\n<\/tr>\n